These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 7634441)

  • 21. Association between the ACE genotype and coronary artery disease. Insights from studies on restenosis, vasomotion and thrombosis.
    Bauters C; Amouyel P
    Eur Heart J; 1998 Sep; 19 Suppl J():J24-9. PubMed ID: 9796837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restenosis after delayed coronary angioplasty of the culprit vessel in patients with a recent myocardial infarction treated by thrombolysis.
    Bauters C; Khanoyan P; McFadden EP; Quandalle P; Lablanche JM; Bertrand ME
    Circulation; 1995 Mar; 91(5):1410-8. PubMed ID: 7867181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis.
    Ludwig E; Corneli PS; Anderson JL; Marshall HW; Lalouel JM; Ward RH
    Circulation; 1995 Apr; 91(8):2120-4. PubMed ID: 7697839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients.
    Prisco D; Fatini C; Battaglini B; Gensini F; Fedi S; Falai M; Chioccioli M; Gori AM; Margheri M; Gensini GF
    Int J Clin Lab Res; 2000; 30(4):179-85. PubMed ID: 11289708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosis.
    Rodriguez A; Santaera O; Larribeau M; Sosa MI; Palacios IF
    Am J Cardiol; 1993 Jun; 71(16):1391-5. PubMed ID: 8517382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial.
    Meurice T; Bauters C; Hermant X; Codron V; VanBelle E; Mc Fadden EP; Lablanche J; Bertrand ME; Amouyel P
    Lancet; 2001 Apr; 357(9265):1321-4. PubMed ID: 11343737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele.
    Okumura K; Sone T; Kondo J; Tsuboi H; Mukawa H; Tsuzuki M; Imai H; Kamiya H; Mabuchi Y; Matsui H; Hayakawa T
    Circ J; 2002 Apr; 66(4):311-6. PubMed ID: 11954942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACE polymorphism, a genetic predictor of occlusion after coronary angioplasty.
    Hamon M; Amant C; Bauters C; Lablanche JM; Bertrand M; Amouyel P
    Am J Cardiol; 1996 Sep; 78(6):679-81. PubMed ID: 8831406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study.
    Pfohl M; Koch M; Prescod S; Haase KK; Häring HU; Karsch KR
    Eur Heart J; 1999 Sep; 20(18):1318-25. PubMed ID: 10462466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis.
    Ribichini F; Steffenino G; Dellavalle A; Matullo G; Colajanni E; Camilla T; Vado A; Benetton G; Uslenghi E; Piazza A
    Circulation; 1998 Jan; 97(2):147-54. PubMed ID: 9445166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Luminal narrowing after percutaneous transluminal coronary angioplasty. A multivariate analysis of clinical, procedural and lesion related factors affecting long-term angiographic outcome in the PARK study. Post-Angioplasty Restenosis Ketanserin.
    Melkert R; Violaris AG; Serruys PW
    J Invasive Cardiol; 1994 Jun; 6(5):160-71. PubMed ID: 10155065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group.
    Rensing BJ; Hermans WR; Vos J; Tijssen JG; Rutch W; Danchin N; Heyndrickx GR; Mast EG; Wijns W; Serruys PW
    Circulation; 1993 Sep; 88(3):975-85. PubMed ID: 8353925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maximal myocardial perfusion by videodensitometry in the assessment of the early and late results of coronary angioplasty: relationship with coronary artery measurements and left ventricular function at rest.
    Vassanelli C; Menegatti G; Molinari J; Zanotto G; Zanolla L; Loschiavo I; Zardini P
    Cathet Cardiovasc Diagn; 1995 Apr; 34(4):301-10; discussion 311-2. PubMed ID: 7621539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease.
    Winkelmann BR; Nauck M; Klein B; Russ AP; Böhm BO; Siekmeier R; Ihnken K; Verho M; Gross W; März W
    Ann Intern Med; 1996 Jul; 125(1):19-25. PubMed ID: 8644984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of angiotensin converting enzyme insertion/deletion polymorphism on long-term total graft occlusion after coronary artery bypass surgery.
    Dayi SU; Tartan Z; Terzi S; Kasikcioglu H; Uyarel H; Orhan G; Alper AT; Ciloglu F; Cam N
    Heart Surg Forum; 2005; 8(5):E373-7. PubMed ID: 16146835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease.
    Nakauchi Y; Suehiro T; Yamamoto M; Yasuoka N; Arii K; Kumon Y; Hamashige N; Hashimoto K
    Atherosclerosis; 1996 Sep; 125(2):161-9. PubMed ID: 8842348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
    Serruys PW; Klein W; Tijssen JP; Rutsch W; Heyndrickx GR; Emanuelsson H; Ball SG; Decoster O; Schroeder E; Liberman H
    Circulation; 1993 Oct; 88(4 Pt 1):1588-601. PubMed ID: 8403306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual determination of angiotensin-converting enzyme and angiotensin-II type 1 receptor genotypes as predictors of restenosis after coronary angioplasty.
    Hamon M; Amant C; Bauters C; Richard F; Helbecque N; Passard F; McFadden EP; Lablanche JM; Bertrand ME; Amouyel P
    Am J Cardiol; 1998 Jan; 81(1):79-81. PubMed ID: 9462611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.